Central nervous system prophylaxis in adults with acute lymphoblastic leukemia: Current and emerging therapies

Cancer

Volumn 116, Issue 10, 2010, Pages 2290-2300

  Jabbour, Elias ^a   Thomas, Deborah ^a   Cortes, Jorge ^a   Kantarjian, Hagop M ^a   O'Brien, Susan ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Acute lymphoblastic leukemia; Central nervous system prophylaxis; Cytarabine; Intrathecal chemotherapy; Liposomal cytarabine; Methotrexate

Indexed keywords

CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; DOXORUBICIN; METHOTREXATE; VINCRISTINE; ANTINEOPLASTIC AGENT;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADULT; BLOOD BRAIN BARRIER; CANCER RECURRENCE; CENTRAL NERVOUS SYSTEM METASTASIS; CLINICAL FEATURE; DRUG CEREBROSPINAL FLUID LEVEL; DRUG MEGADOSE; EVENT FREE SURVIVAL; HUMAN; MENINGITIS; PRIORITY JOURNAL; PROPHYLAXIS; REVIEW; RISK FACTOR; SKULL IRRADIATION; SURVIVAL TIME; SYSTEMIC THERAPY; CANCER INVASION; CARCINOMATOUS MENINGITIS; CENTRAL NERVOUS SYSTEM; INTRASPINAL DRUG ADMINISTRATION; MENINGIOMA; PATHOLOGY; RECURRENT DISEASE;

ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CENTRAL NERVOUS SYSTEM; CRANIAL IRRADIATION; HUMANS; INJECTIONS, SPINAL; LEUKEMIC INFILTRATION; MENINGEAL CARCINOMATOSIS; MENINGEAL NEOPLASMS; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; RECURRENCE;

EID: 77952566967     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.25008     Document Type: Review

References (92)

1. Jemal A, Tiwari RC, Murray T, et al. Cancer statistics, 2004. CA Cancer J Clin. 2004;54:8-29.
2. Groves FD, Linet MS, Devesa SS. Epidemiology of leukemia: overview of patterns of occurrence. In: Henderson ES, Sister TA, Greaves MF, eds. Leukemia. 6th ed. Philadelphia, Pa: WB Saunders Company; 1996:145-159.
3. Greaves M. In utero origins of childhood leukaemia. Early Hum Dev. 2005;81:123-129.
4. Mahieux R, Gessain A. HTLV-1 and associated adult T-cell leukemia/lymphoma. Rev Clin Exp Hematol. 2003;7:336-361. (Pubitemid 38248510)
5. Lombardi L, Newcomb EW, Dalla-Favera R. Pathogenesis of Burkitt lymphoma: expression of an activated c-myc oncogene causes the tumorigenic conversion of EBV-infected human B lymphoblasts. Cell. 1987;49:161-170. (Pubitemid 18089603)
6. Larson RA. Management of acute lymphoblastic leukemia in older patients. Semin Hematol. 2006;43:126-133.
7. Gokbuget N, Hoelzer D. Treatment of adult acute lymphoblastic leukemia [serial online]. Hematology Am Soc Hematol Educ Program. 2006;133-141.
8. Evans AE, Gilbert ES, Zandstra R. The increasing incidence of central nervous system leukemia in children. Cancer. 1970;26:404-409.
9. Bleyer WA, Poplack DG. Prophylaxis and treatment of leukemia in the central nervous system and other sanctuaries. Semin Oncol. 1985;12:131-148. (Pubitemid 15065137)
10. Smith M, Arthur D, Camitta B, et al. Uniform approach to risk classification and treatment assignment for children with acute lymphoblastic leukemia. J Clin Oncol. 1996; 14:18-24.
11. Lange B, Bostrom B, Cherlow JM, et al. Double-delayed intensification improves event free survival for children with intermediate risk acute lymphoblastic leukemia: a report from the Children's Cancer Group. Blood. 2002;99:825-833.
12. Hutchinson RJ, Gaynon PS, Sather H, et al. Children's Cancer Group/Children's Oncology Group. Intensification of therapy for children with lower-risk acute lymphoblastic leukemia: long-term follow-up of patients treated on Children's Cancer Group Trial 1881. J Clin Oncol. 2003;21: 1790-1797.
13. Pui C-H. Central nervous system disease in acute lymphoblastic leukemia: prophylaxis and treatment [serial online]. Hematology Am Soc Hematol Educ Program. 2006:142-146.
14. Schiffer CA. Differences in outcome in adolescents with acute lymphoblastic leukemia: a consequence of better regimens? Better doctors? Both? J Clin Oncol. 2003;21:760-761.
15. Seibel NL, Steinherz PG, Sather HN, et al. Early postinduction intensification therapy improves survival for children and adolescents with high-risk acute lymphoblastic leukemia: a report from the Children's Oncology Group. Blood. 2008;111:2548-2555.
16. Lazarus HM, Richards SM, Chopra R, et al. Medical Research Council (MRC)/National Cancer Research Institute (NCRI) Adult Leukaemia Working Party of the United Kingdom and the Eastern Cooperative Oncology Group. Central nervous system involvement in adult acute lymphoblastic leukemia at diagnosis: results from the international ALL trial MRC UKALL-XII/ECOG E2993. Blood. 2006; 108:465-472.
17. Reman O, Pigneux A, Huguet F, et al. GET-LALA Group. Central nervous system involvement in adult acute lymphoblastic leukemia at diagnosis and/or first relapse: results from the GET-LALA Group. Leuk Res. 2008;32:1741-1750.
18. Hedge U, Filie A, Little RF, et al. High incidence of occult leptomeningeal disease detected by flow cytometry in newly diagnosed aggressive B-cell lymphomas at risk for central nervous system involvement: the role of flow cytometry versus cytology. Blood. 2005;105:496-502.
19. Omura GA, Moffitt S, Vogler WR, Salter MM. Combination chemotherapy of adult acute lymphoblastic leukemia with randomized central nervous system prophylaxis. Blood. 1980;55:199-204. (Pubitemid 10161191)
20. Surapaneni UR, Cortes JE, Thomas D, et al. Central nervous system relapse in adults with acute lymphoblastic leukemia. Cancer. 2002;94:773-779. (Pubitemid 34132307)
21. Chamberlain MC. Neoplastic meningitis. Neurologist. 2006;12:179-187.
22. Chamberlain MC. Lymphomatous meningitis in primary central nervous system lymphoma [serial online]. Neurosurg Focus. 2006;21:E6.
23. Wasserstrom WR, Glass JP, Posner JB. Diagnosis and treatment of leptomeningeal metastases from solid tumors. Cancer. 1982;49:759-772.
24. Gleissner B, Chamberlain MC. Neoplastic meningitis. Lancet Neurol. 2006;5:443-452.
25. Fielding AK, Richards SM, Chopra R, et al. Eastern Cooperative Oncology Group. Outcome of 609 adults after relapse of acute lymphoblastic leukemia (ALL): an MRC UKALL 12/ECOG 2993 study. Blood. 2007;109: 944-950.
26. Sancho JM, Ribera JM, Oriol A, et al. Programa para el Estudio y Tratamiento de Hemopatias Malignas Group. Central nervous system recurrence in adult patients with acute lymphoblastic leukemia: frequency and prognosis in 467 patients without cranial irradiation for prophylaxis. Cancer. 2006;106:2540-2546.
27. Chamberlain MC, Nolan C, Abrey LE. Leukemic and lymphomatous meningitis: incidence, prognosis and treatment. J Neuro-Oncol. 2005;75:71-83. (Pubitemid 41548680)
28. Cortes J, O'Brien SM, Pierce S, Keating MJ, Freireich EJ, Kantarjian HM. The value of high-dose systemic chemotherapy and intrathecal therapy for central nervous system prophylaxis in different risk groups of adult acute lymphoblastic leukemia. Blood. 1995;86:2091-2097.
29. Cortes J. Central nervous system involvement in adult acute lymphocytic leukemia. Hematol Oncol Clin North Am. 2001;15:145-162. (Pubitemid 32201871)
30. Bassan R, Gatta G, Tondini C, Willemze R. Central nervous system involvement in adult acute lymphoblastic leukaemia: retrospective analysis from the Northern Italy Leukaemia Group (NILG) on 687 total patients (1979-2004). Abstract 0418. Presented at the 10th Congress of the European Hematology Association, Stockholm, Sweden, June 2-5, 2005.
31. Kantarjian HM, Walters RS, Smith TL, et al. Identification of risk groups for development of central nervous system leukemia in adults with acute lymphocytic leukemia. Blood. 1988;72:1784-1789.
32. Moorman AV, Harrison CJ, Buck GA, et al. Adult Leukaemia Working Party, Medical Research Council/National Cancer Research Institute. Karyotype is an independent prognostic factor in adult acute lymphoblastic leukemia (ALL): analysis of cytogenetic data from patients treated on the Medical Research Council (MRC) UKALLXII/Eastern Cooperative Oncology Group (ECOG) 2993 trial. Blood. 2007;109:3189-3197.
33. Sharathkumar A, DeCamillo D, Bhambhani K, et al. Children with hyperdiploid but not triple trisomy (+4, +10, +17) acute lymphoblastic leukemia have an increased incidence of extramedullary relapse on current therapies: a single institution experience. Am J Hematol. 2008;83:34-40.
34. Mahmoud HH, Rivera GK, Hancock ML, et al. Low leukocyte counts with blast cells in cerebrospinal fluid of children with newly diagnosed acute lymphoblastic leukemia. N Engl J Med. 1993;329:314-319.
35. Pui C-H. Toward optimal central nervous system-directed treatment in childhood acute lymphoblastic leukemia. J Clin Oncol. 2003;21:179-181.
36. Medical Research Council by the Leukemia Committee and the Working Party on Leukemia in Childhood. Treatment of acute lymphoblastic leukemia: effect of "prophylactic" therapy against central nervous system leukemia. BMJ. 1973;2:381-384.
37. Ribeiro RC, Rivera GK, Hudson M, et al. An intensive re-treatment protocol for children with an isolated CNS relapse of acute lymphoblastic leukemia. J Clin Oncol. 1995;13:333-338.
38. Ritchey AK, Pollock BH, Lauer SJ, Andejeski Y, Barredo J, Buchanan GR. Improved survival of children with isolated CNS relapse of acute lymphoblastic leukemia: a Pediatric Oncology Group study. J Clin Oncol. 1999;17:3745-3752.
39. Simone J, Aur RJA, Hustu HO, Pinkel D. "Total therapy" studies of acute lymphocytic leukemia in children: current results and prospects for care. Cancer. 1972;30:1488-1494.
40. Pui C-H, Dodge RK, Look AT, et al. Risk of adverse events in children completing treatment for acute lymphoblastic leukemia: St. Jude total therapy studies VIII, IX, X. J Clin Oncol. 1991;9:1341-1347.
41. Sanders KE, Ha CS, Cortes-Franco JE, Koller CA, Kantarjian HM, Cox JD. The role of craniospinal irradiation in adults with a central nervous system recurrence of leukemia. Cancer. 2004;100:2176-2180.
42. Pui C-H, Cheng C, Leung W, et al. Extended follow-up of long-term survivors of childhood acute lymphoblastic leukemia. N Engl J Med. 2003;349:640-649.
43. Byrne J, Fears TR, Steinhorn SC, et al. Marriage and divorce after childhood and adolescent cancer. JAMA. 1989; 262:2693-2699.
44. Haupt R, Fears TR, Robison LL, et al. Educational attainment in long-term survivors of childhood acute lymphoblastic leukemia. JAMA. 1994;272:1427-1432.
45. Laack NN, Brown PD. Cognitive sequelae of brain radiation in adults. Semin Oncol. 2004;31:702-713.
46. Tucker J, Prior PF, Green CR, et al. Minimal neuropsychological sequelae following prophylactic treatment of the central nervous system in adult leukemia and lymphoma. Br J Cancer. 1989;60:775-780.
47. Vilmer E, Suciu S, Ferster A, et al. Long-term results of 3 randomized trials (58831, 58832, 58881) in childhood acute lymphoblastic leukemia: a CLCG-EORTC report. Children Leukemia Cooperative Group. Leukemia. 2000;14: 2257-2266.
48. Manera R, Ramirez I, Mullins J, Pinkel D. Pilot studies of species-specific chemotherapy of childhood acute lymphoblastic leukemia using genotype and immunophenotype. Leukemia. 2000;14:1354-1361. (Pubitemid 30599315)
49. Annino L, Vegna ML, Camera A, et al. GIMEMA Group. Treatment of adult acute lymphoblastic leukemia (ALL): long-term follow-up of the GIMEMA ALL 0288 randomized study. Blood. 2002;99:863-871.
50. Kantarjian HM, O'Brien S, Smith TL, et al. Results of treatment with hyper-CVAD, a dose-intensive regimen, in adult acute lymphocytic leukemia. J Clin Oncol. 2000;18: 547-561.
51. Schrappe M, Reiter A, Ludwig W-D, et al. Improved outcome in childhood acute lymphoblastic leukemia despite reduced use of anthracyclines and cranial radiotherapy: results of trial ALL-BFM 90. German-Austrian-Swiss ALL-BFM Study Group. Blood. 2000;95:3310-3322.
52. Chang JE, Medlin SC, Kahl BS, et al. Augmented and standard Berlin-Frankfurt-Munster chemotherapy for treatment of adult acute lymphoblastic leukemia. Leuk Lymphoma. 2008;49:2298-2307.
53. Gokbuget N, Hoelzer D. High-dose methotrexate in the treatment of adult lymphoblastic leukemia. Ann Hematol. 1996;72:194-201. (Pubitemid 26125814)
54. Muldoon LL, Soussain C, Jahnke K, et al. Chemotherapy delivery issues in central nervous system malignancy: a reality check. J Clin Oncol. 2007;25:2295-2305.
55. Rudnick SA, Cadman EC, Capizzi RL, Skeel RT, Bertino JR, McIntosh S. High dose cytosine arabinoside (HDARAC) in refractory acute leukemia. Cancer. 1979;44:1189-1193.
56. Capizzi RL, Yang JL, Cheng E, et al. Alteration of the pharmacokinetics of high-dose AraC by its metabolite, high AraU in patients with acute leukemia. J Clin Oncol. 1983;1:763-771. (Pubitemid 14167250)
57. Hande KR, Stein RS, McDonough DA, Greco FA, Wolff SN. Effects of high-dose cytarabine. Clin Pharmacol Ther. 1982;31:669-674.
58. Ackland SP, Schilsky RL. High-dose methotrexate: a critical reappraisal. J Clin Oncol. 1987;5:2017-2031.
59. Childhood ALL Collaborative Group. Duration and intensity of maintenance chemotherapy in acute lymphoblastic leukemia: overview of 42 trials involving 12 000 randomised children. Lancet. 1996;347:1783-1788.
60. Balis FM, Lester CM, Chrousos GP, Heideman RL, Poplack DG. Differences in cerebrospinal fluid penetration of corticosteroids: possible relationship to the prevention of meningeal leukemia. J Clin Oncol. 1987;5:202-207.
61. Bostrom BC, Sensel MR, Sather HN, et al. Children's Cancer Group. Dexamethasone versus prednisone and daily oral versus weekly intravenous mercaptopurine for patients with standard-risk acute lymphoblastic leukemia: a report from the Children's Cancer Group. Blood. 2003;101:3809-3817.
62. Jones B, Freeman AI, Shuster JJ, et al. Lower incidence of meningeal leukemia when prednisone is replaced by dexamethasone in the treatment of acute lymphocytic leukemia. Med Pediatr Oncol. 1991;19:269-275.
63. Mitchell, CD, Richards SM, Kinsey SE, Lilleyman J, Vora A, Eden TO; Medical Research Council Childhood Leukaemia Working Party. Benefit of dexamethasone compared with prednisolone for childhood acute lymphoblastic leukemia: results of the UK Medical Research Council ALL97 randomized trial. Br J Hematol. 2005;129:734-745.
64. Wellwood J, Taylor K. Central nervous system prophylaxis in hematological malignancies. Int Med J. 2002;32:252-258.
65. DeAngelis L. Primary CNS lymphoma: is there a role for prophylaxis against lymphomatous meningitis? Expert Rev Neurother. 2004;4(suppl 1):S19-S21.
66. Hill QA, Owen RG. CNS prophylaxis in lymphoma: who to target and what therapy to use. Blood Rev. 2006;20:319-332.
67. Pui C-H, Mahmoud HH, Rivera GK, et al. Early intensification of intrathecal chemotherapy virtually eliminates central nervous system relapse in children with acute lymphoblastic leukemia. Blood. 1998;92:411-415.
68. Dekker MB, van't Veer, Sizoo W, Haak HL, et al. Intensive postremission chemotherapy without maintenance therapy in adults with acute lymphoblastic leukemia. Dutch Hemato-Oncology Research Group. J Clin Oncol. 1997;15:476-482.
69. Storring JM, Minden MD, Kao S, et al. Treatment of adults with BCR-ABL negative acute lymphoblastic leukaemia with a modified paediatric regimen. Br J Haematol. 2009;146:76-85.
70. Stock W, La M, Sanford B, et al. Children's Cancer Group; Cancer and Leukemia Group B studies. What determines the outcomes for adolescents and young adults with acute lymphoblastic leukemia treated on cooperative group protocols? A comparison of Children's Cancer Group and Cancer and Leukemia Group B studies. Blood. 2008;113:1646-1654.
71. Pacira Pharmaceuticals. DepoCyt (liposomal cytarabine) prescribing information. San Diego, Calif: Pacira Pharmaceuticals; 2007.
72. Tsuchiya J, Moteki M, Shimano S, et al. Proliferative kinetics of the leukemic cells in meningeal leukemia. Cancer. 1978;42:1255-1262. (Pubitemid 9054588)
73. Chamberlain MC, Kormanik P, Howell SB, Kim S. Pharmacokinetics of intralumbar DTC 101 for the treatment of leptomeningeal metastases. Arch Neurol. 1995;52:912-917.
74. Kim S, Chatelut E, Kim J, et al. Extended CSF cytarabine exposure following intrathecal administration of DTC 101. J Clin Oncol. 1993;11:2186-2193. (Pubitemid 23332256)
75. Shapiro WR, Young DF, Mehta BM. Methotrexate: distribution in cerebrospinal fluid after intravenous, ventricular and lumbar injections. N Engl J Med. 1975;293:161-166.
76. Perrin RG, Lishner M, Guha A, Curtis J, Feld R, Messner H. Experience with Ommaya reservoir in 120 consecutive patients with meningeal malignancy. Can J Neurol Sci. 1990;17:190-192. (Pubitemid 20177536)
77. Obbens EA, Leavens ME, Beal JW, Lee YY. Ommaya reservoirs in 387 cancer patients: a 15-year experience. Neurology. 1985;35:1274-1278.
78. Sandberg DI, Bilsky MH, Souweidane MM, Bzdil J, Gutin PH. Ommaya reservoirs for the treatment of leptomeningeal metastases. Neurosurgery. 2000;47:49-54.
79. Fleischhack G, Jaehde U, Bode U. Pharmacokinetics following intraventricular administration of chemotherapy in patients with neoplastic meningitis. Clin Pharmacokinetics. 2005;44:1-31. (Pubitemid 40096037)
80. Thomas DA, Faderl S, O'Brien S, et al. Chemoimmunotherapy with hyper-CVAD and rituximab for the treatment of adult Burkitt and Burkitt-type lymphoma or acute lymphoblastic leukemia. Cancer. 2006;106:1569-1580.
81. Jabbour E, O'Brien S, Kantarjian H, et al. Neurological complications associated with intrathecal liposomal cytarabine given prophylactically in combination with high-dose methotrexate and cytarabine to patients with acute lymphocytic leukemia. Blood. 2007;109:3214-3218.
82. Thomas DA, Jabbour E, Kantarjian H, O'Brien S. Neurologic toxicity of intrathecal liposomal cytarabine when used for CNS prophylaxis in conjunction with the hyper-CVAD regimen [correspondence]. Blood. 2007;110:1698-1699. (Pubitemid 47443990)
83. Chamberlain MC, Glantz J. Neurologic complications associated with intrathecal liposomal cytarabine given prophylactically in combination with high-dose methotrexate and cytarabine to patients with acute lymphocytic leukemia. [correspondence]. Blood. 2007;110:1698.
84. McClune B, Buadi FK, Aslam N, Prsepiorka D. Intrathecal liposomal cytarabine for prevention of meningeal disease in patients with acute lymphoblastic leukemia and high-grade lymphoma. Leuk Lymphoma. 2007;9:1849-1851. (Pubitemid 47386722)
85. Baker J, Royer GL, Weiss RB. Cytarabine and neurologic toxicity. J Clin Oncol. 1991;9:679-693.
86. Hilgendorf I, Woff D, Junghanss C, et al. Neurological complications after intrathecal liposomal cytarabine application in patients after allogenic haematopoietic stem cell transplantation. Ann Hematol. 2008;87:1009-1012.
87. Pui CH. Toward optimal use of intrathecal liposomal cytarabine. Leuk Lymphoma. 2007;48:1672-1673.
88. Viele CS. Diagnosis, treatment, and nursing care of acute leukemia. Semin Oncol Nurs. 2003;19:98-108.
89. Larson RA. Acute lymphoblastic leukemia: older patients and newer drugs [serial online]. Hematology Am Soc Hematol Educ Program. 2005:131-136.
90. Goldstone AH, Prentice HG, Durrant J, et al. Allogenic transplant (related or unrelated donor) is the preferred treatment for acute adult Philadelphia positive (Ph+) acute lymphoblastic leukaemia (ALL). Results from the international ALL trial (MRC UKALLXII/ECOG E2993) [abstract]. Blood. 2001;98:856a. Abstract 3556.
91. Takayama N, Sato N, O'Brien SG, Ikeda Y, Okamoto S. Imatinib mesylate has limited activity against the central nervous system involvement of Philadelphia chromosome-positive acute lymphoblastic leukaemia because of poor penetration into cerebrospinal fluid. Br J Haematol. 2002;119:106-108.
92. Porkka K, Koskenvesa P, Ludan T, et al. Dasatinib crosses the blood-brain barrier and is an efficient therapy for central nervous system Philadelphia chromosome-positive leukemia. Blood. 2008;112:1005-1012.